Business news – Page 104
-
Opinion'Pay for delay'
Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal
-
Business
Business roundup: September 2011
Challenges for the drugs to help you quit Source: © Shutterstock Tobacco kills six million people every year The share price of US-based Nabi Biopharmaceuticals has fallen by 70 per cent after it announced that its nicotine addiction treatment, NicVax, failed to reach its endpoint in the ...
-
OpinionThe pitfalls that prevent progress
Derek Lowe highlights the less visible pitfalls on the road to a new drug
-
Business
Business roundup: August 2011
Companies making moves into Russia Several companies have made recent moves into Russia. Novartis has started building a new manufacturing site in St Petersburg. The site - to be completed by 2014 - will produce generic as well as branded drugs and create 350 jobs for local people. Novartis says ...
-
OpinionThe financial funfair
The financial markets can be a rollercoaster ride, writes Derek Lowe, so should chemists working in industry worry about the company share price?
-
Business
Business roundup: July 2011
World digs deep for cheaper vaccination Source: © Ben Fisher/GAVI/2011 UK Prime M inister David Cameron talked of a ’vital issue’ World leaders have pledged $4.3 billion (£2.6 billion) over the next five years to vaccinate 250 million people in developing countries with the help of the ...
-
OpinionCategorising chemists
To the unfamiliar, chemists might all look the same. But some common categories are easy to identify, explains Derek Lowe
-
Business
Business roundup: June 2011
Succinic acid plans Dutch life and material sciences company DSM and French starch company Roquette Frères are together planning to build what they say will be the largest European plant for the production of succinic acid from biological sources. To be built on the Roquette site at Cassano Spinola ...
-
OpinionWho counts as a chemist?
The map of scientific disciplines is growing ever more complex. Derek Lowe surveys the country
-
Business
Business roundup: May 2011
Pharmaceutical US approval for AZ thyroid cancer drug The US Food and Drug Administration (FDA) has approved orphan drug vandetanib for the treatment of thyroid cancer. The drug candidate is owned by pharma major AstraZeneca. The approval refers to medullary thyroid cancer that cannot be removed by surgery or ...
-
OpinionThe return of the return of natural products
'Natural products are back!' is a headline Derek Lowe has seen several times before
-
Business
Business roundup: April 2011
Pharmaceutical Forest pays $1.2bn for Clinical Data US pharma company Forest Laboratories has agreed to buy Clinical Data for $30 (£19) per share in cash, equivalent to $1.2 billion, plus $6 per share payable if Viibryd (vilazodone) reaches commercial milestones. Forest intends to use existing cash to finance the deal. ...
-
OpinionThe risk vs reward of drug discovery
Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
-
Business
Business roundup: March 2011
Venom kits for drug discovery research Drug discovery companies can now buy venom kits to help them find new avenues of investigation by high throughput screening. Each kit from Swiss company Bachem is a plate with a series of wells - each well contains peptide fragments from the venoms ...
-
OpinionElevating enzymes
Enzymes have been giving chemists inferiority complexes since day one, says Derek Lowe. But there's no denying their potential
-
Business
Business roundup: February 2011
DuPont signs $6.3 billion Danisco deal Source: © Danisco Danisco divested its flavour and sugar businesses in the last five years US chemical major DuPont has agreed to buy Danish food ingredients and enzymes company Danisco for $5.8 billion (£3.7 billion), plus $500 million of Danisco ...
-
OpinionFluorine fanatics
Some medicinal chemists can't get enough fluorines in their molecules. Derek Lowe explains the love-hate relationship
-
Business
Business roundup: January 2011
New pharma bosses take up challenge Can Ian Read (L) and Ken Frazier (R) solve the big pharma problem? Two of the big US pharma companies have appointed new chief executives. Jeff Kindler has unexpectedly retired from Pfizer after four and a half years as chief ...
-
OpinionWe need more surprises
Who's that asleep at the back? Don't be too quick to blame yourself when tedious talks and soporific seminars fail to inspire, says Derek Lowe
-
Business
Business roundup: December 2010
Polished performance from Pradaxa The US Food and Drug Administration (FDA) has approved Pradaxa (dabigatran), made by Boehringer Ingelheim, for the prevention of stroke and blood clots in patients with abnormal heart rhythm, known as atrial fibrillation. Source: © Paul Gunning / Science Photo Library ...